Company news

Inhibikase Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

October 27, 2026

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors

October 20, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

August 11, 2026

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

July 23, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility

July 15, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

July 14, 2026

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

May 12, 2026

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

April 7, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

April 6, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

March 26, 2026

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

November 20, 2025

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 20, 2025

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

November 20, 2025

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

November 14, 2025

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

August 19, 2025

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

August 15, 2025

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

August 14, 2025

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

April 14, 2025

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

March 27, 2025

Inhibikase Announces Expansion of Senior Leadership Team

February 24, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

February 18, 2025

Market Offering Agreement Form 8 K

December 5, 2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

November 14, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT 001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension Form 8 K

October 22, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

October 21, 2024

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.